The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea

J. Mar, J. R. Rueda, J. Durán-Cantolla, Clyde B. Schechter, J. Chilcott

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

The demand for diagnostic and therapeutic services for obstructive sleep apnoea syndrome (OSAS) showed marked growth during the 1990s. This paper analyses the long-term cost-effectiveness of nasal continuous positive airway pressure (nCPAP) treatment in comparison to conventional null treatment. A Markov model was used to represent the natural history of OSAS based upon published evidence. Utility values came from a survey of OSAS patients. Data on health costs were collected from hospitals in the Basque Country, Spain. The incremental cost-effectiveness ratio of nCPAP treatment is <6,000 Euros per quality-adjusted life year. On disaggregated analysis, nCPAP treatment accounts for 86% of incremental costs; 84% of incremental effectiveness is attributable to improved quality of life. Treatment of obstructive sleep apnoea syndrome with nasal continuous positive airway pressure has a cost-effectiveness that is in line with that of other commonly funded treatments such as antihypertensive drugs. The key clinical benefit of nasal continuous positive airway pressure treatment is improvement in the quality of life of patients with obstructive sleep apnoea syndrome. This benefit is also precisely the one for which the evidence base is strongest. The remaining uncertainties concerning the impact of nasal continuous positive airway pressure on long-term mortality have only a relatively small impact on the economics of treatment.

Original languageEnglish (US)
Pages (from-to)515-522
Number of pages8
JournalEuropean Respiratory Journal
Volume21
Issue number3
StatePublished - Mar 1 2003

Fingerprint

Continuous Positive Airway Pressure
Obstructive Sleep Apnea
Cost-Benefit Analysis
Therapeutics
Quality of Life
Diagnostic Services
Quality-Adjusted Life Years
Health Care Costs
Spain
Antihypertensive Agents
Uncertainty
Economics
Costs and Cost Analysis
Mortality

Keywords

  • Cost-effectiveness analysis
  • Markov chains
  • Obstructive sleep apnoea syndrome
  • Quality of life

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea. / Mar, J.; Rueda, J. R.; Durán-Cantolla, J.; Schechter, Clyde B.; Chilcott, J.

In: European Respiratory Journal, Vol. 21, No. 3, 01.03.2003, p. 515-522.

Research output: Contribution to journalArticle

Mar, J. ; Rueda, J. R. ; Durán-Cantolla, J. ; Schechter, Clyde B. ; Chilcott, J. / The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea. In: European Respiratory Journal. 2003 ; Vol. 21, No. 3. pp. 515-522.
@article{d4cc851449ea4f6bb20aff28071ed800,
title = "The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea",
abstract = "The demand for diagnostic and therapeutic services for obstructive sleep apnoea syndrome (OSAS) showed marked growth during the 1990s. This paper analyses the long-term cost-effectiveness of nasal continuous positive airway pressure (nCPAP) treatment in comparison to conventional null treatment. A Markov model was used to represent the natural history of OSAS based upon published evidence. Utility values came from a survey of OSAS patients. Data on health costs were collected from hospitals in the Basque Country, Spain. The incremental cost-effectiveness ratio of nCPAP treatment is <6,000 Euros per quality-adjusted life year. On disaggregated analysis, nCPAP treatment accounts for 86{\%} of incremental costs; 84{\%} of incremental effectiveness is attributable to improved quality of life. Treatment of obstructive sleep apnoea syndrome with nasal continuous positive airway pressure has a cost-effectiveness that is in line with that of other commonly funded treatments such as antihypertensive drugs. The key clinical benefit of nasal continuous positive airway pressure treatment is improvement in the quality of life of patients with obstructive sleep apnoea syndrome. This benefit is also precisely the one for which the evidence base is strongest. The remaining uncertainties concerning the impact of nasal continuous positive airway pressure on long-term mortality have only a relatively small impact on the economics of treatment.",
keywords = "Cost-effectiveness analysis, Markov chains, Obstructive sleep apnoea syndrome, Quality of life",
author = "J. Mar and Rueda, {J. R.} and J. Dur{\'a}n-Cantolla and Schechter, {Clyde B.} and J. Chilcott",
year = "2003",
month = "3",
day = "1",
language = "English (US)",
volume = "21",
pages = "515--522",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

TY - JOUR

T1 - The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea

AU - Mar, J.

AU - Rueda, J. R.

AU - Durán-Cantolla, J.

AU - Schechter, Clyde B.

AU - Chilcott, J.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - The demand for diagnostic and therapeutic services for obstructive sleep apnoea syndrome (OSAS) showed marked growth during the 1990s. This paper analyses the long-term cost-effectiveness of nasal continuous positive airway pressure (nCPAP) treatment in comparison to conventional null treatment. A Markov model was used to represent the natural history of OSAS based upon published evidence. Utility values came from a survey of OSAS patients. Data on health costs were collected from hospitals in the Basque Country, Spain. The incremental cost-effectiveness ratio of nCPAP treatment is <6,000 Euros per quality-adjusted life year. On disaggregated analysis, nCPAP treatment accounts for 86% of incremental costs; 84% of incremental effectiveness is attributable to improved quality of life. Treatment of obstructive sleep apnoea syndrome with nasal continuous positive airway pressure has a cost-effectiveness that is in line with that of other commonly funded treatments such as antihypertensive drugs. The key clinical benefit of nasal continuous positive airway pressure treatment is improvement in the quality of life of patients with obstructive sleep apnoea syndrome. This benefit is also precisely the one for which the evidence base is strongest. The remaining uncertainties concerning the impact of nasal continuous positive airway pressure on long-term mortality have only a relatively small impact on the economics of treatment.

AB - The demand for diagnostic and therapeutic services for obstructive sleep apnoea syndrome (OSAS) showed marked growth during the 1990s. This paper analyses the long-term cost-effectiveness of nasal continuous positive airway pressure (nCPAP) treatment in comparison to conventional null treatment. A Markov model was used to represent the natural history of OSAS based upon published evidence. Utility values came from a survey of OSAS patients. Data on health costs were collected from hospitals in the Basque Country, Spain. The incremental cost-effectiveness ratio of nCPAP treatment is <6,000 Euros per quality-adjusted life year. On disaggregated analysis, nCPAP treatment accounts for 86% of incremental costs; 84% of incremental effectiveness is attributable to improved quality of life. Treatment of obstructive sleep apnoea syndrome with nasal continuous positive airway pressure has a cost-effectiveness that is in line with that of other commonly funded treatments such as antihypertensive drugs. The key clinical benefit of nasal continuous positive airway pressure treatment is improvement in the quality of life of patients with obstructive sleep apnoea syndrome. This benefit is also precisely the one for which the evidence base is strongest. The remaining uncertainties concerning the impact of nasal continuous positive airway pressure on long-term mortality have only a relatively small impact on the economics of treatment.

KW - Cost-effectiveness analysis

KW - Markov chains

KW - Obstructive sleep apnoea syndrome

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=0037342247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037342247&partnerID=8YFLogxK

M3 - Article

C2 - 12662011

AN - SCOPUS:0037342247

VL - 21

SP - 515

EP - 522

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 3

ER -